AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California. The company trades on NYSE exchange. The company headquarter is located in Irvine, CA.

TickerAEON
Long NameAEON Biopharma, Inc.
Short NameAEON Biopharma